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Background: Cancer of uterine cervix is the second most common cause of cancer related deaths among women.
The aim of this study is to report the experience of Military Hospital Mohamed V in the management of cervical
cancer and their results.
Methods: All cervical cancer managed at the radiotherapy department of Military Hospital Mohamed V between
January 2005 and February 2010, were included for investigation of their demographic, histological, therapeutic and
follow-up characteristics. Of the 162 cases managed, 151 (93.2 %) cases were treated in our department.
Results: In our study the median age was 51.5 years (33–82). The median duration of symptoms before diagnosis
was four [3, 7] months. The major presenting complaints were abnormal vaginal bleeding (89.8 %). Squamous cell
carcinoma cervix was seen in 86.2 % (n = 137), adenocarcinoma in 11.3 % (n = 18) and adenosquamous carcinoma
in 2.4 % (n = 4). One hundred seventeen (84.8 %) cases were seen at late stage. An abdominal and pelvic computed
tomography (CT) scan was performed in 34.6 % (n = 56) of cases, magnetic resonance imaging (MRI) in 62.9 %
(n = 102). The pelvic lymph nodes were achieved in 16.6 % of cases.
Over half of patients 58.3 % (n = 88) were treated with a combination of external beam radiation therapy (EBRT)
and a concurrent cisplatin based chemotherapy (40 mg /m2 weekly).
With a mean of 51.6 months (2 to 109), we recorded 19 (12.6 %) pelvic relapse and 15 (9.9 %) metastases. The
median time to onset was 19.4 months (2–84 months). The local control rate was 63.6 % (n = 96) and 21 (13.9 %)
patients were lost to follow-up. The overall survival (OS) at 3 years and 5 years was respectively 78.3 % and 73.6 %
and the relapse-free survival (RFS) was respectively 80 % and 77.2 %.
Conclusion: Most of cervical cancer patients in Morocco are seen at late stage necessitating referral for
radiotherapy, chemotherapy or palliative care. This may reflect lack of cervical screening in order to early detect and
treat pre-malignant disease stage.
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Cervical cancer is the second most common cancer in
women worldwide [1]. It is estimated that there are
more than 529 000 new cases diagnosed annually and
more than 274,000 deaths in the world in 2008, of which
more than 87 % occur in developing countries [2, 3].
Cervical cancer continues to be related to socio-
economic and demographic (SEDS) disparities in both
developing and developed countries. In the U.S., al-
though the overall downward trend in cervical cancer
there still exists a disproportion in mortality rates for
cervical cancer related deaths among ages, racial, geo-
graphic and socio-economic groups [4, 5]. Analyses of
the USA cancer data have shown that mortality due to
cervical cancer increases with poverty and decreasing
education [6]. Studies have publicized that late stage at
diagnosis is correlated with lower survival rates [7]. It
has also been reported that longer durations of symp-
toms as well as of treatment prolongation negatively
affect survival [8, 9]. These two factors can therefore be
useful predictors for the severity of illness and likelihood
of survival.
In Morocco, cervical cancer is the second most com-
mon cancer of women after breast cancer [10]. According
to GLOBOCAN 2008 [2], the world age-standardized inci-
dence of cervical cancer among women in Morocco was
14.1 new cases/100 000 inhabitants/year (1979 new cases/
year). The mortality rate from this cancer was 8.4 per 100
000. The stage of diagnosis is the most important inde-
pendent factor of prognosis [11, 12]. In Morocco, a recent
study [13] showed a late diagnosis of cervical cancer. In-
deed, 43.7 % were presented with stage II at diagnosis
(FIGO) and 38.1 % were presented in advanced stages
(stages III and IV).
The aim of this study is to report the experience of
Military Hospital Mohamed V in the management of
cervical cancer, the various treatment modalities used
and their results.
Methods
This is a retrospective analytic study of 162 cervical can-
cer patients managed at the radiotherapy department of
Military Hospital Mohamed V of Rabat in Morocco, be-
tween January 2005 and February 2010.
Data was collected using a well structured checklist
containing important study parameters. The record col-
lection includes patient demographic data (age of diagno-
sis, of marriage and age of first pregnancy (years)),
menopausal status (premenopausal or postmenopausal)
and parity was separated on three groups (0, 1–4 and ≥ 5).
Data includes also clinical presenting symptoms (abnor-
mal vaginal bleeding, offensive vaginal discharge, pelvis
pain…), duration of symptoms (months), vaginal invading
(free, upper, medium or lower vaginal wall) and otherclinical data such as classification FIGO of disease (IA, IB,
IIA, IIB, IIIB, IVA, IVB), histological type (squamous,
adenocarcinoma or adenosquamous), pelvic and/or lateral
aortic adenopathy, parametrial invasion, date of primary
diagnosis. The type and modalities of primary treatment
(radiotherapy, chemotherapy, both or/and surgery), date
and sites of relapse (pelvic and/or metastases), the follow
up data, death date and date of last follow-up visit were
also recorded.
Statistical analysis of the data was carried out by the
SPSS for Windows (SPSS, Inc., Chicago, IL, USA).
Qualitative variables were presented as number and per-
centages. Quantitative variables were presented as mean
± standard deviation for variables with normal distribu-
tion, and as median and interquartile range (IQR) for
variables with skewed distributions. The survival rate
was analyzed with the Kaplan-Meier method.
Results
Of the 162 cases of cervical cancer managed, 151
(93.2 %) cases were treated in our department. Table 1
shows their epidemiological characteristics. Their ages
ranged from 33 to 82 years old with a mean of 51.5
(±11.5) years. More than half of patients were post
menopausal 85 (52.5 %) and married early 58 (63.7 %).
Age of first pregnancy ranged from 14 to 36 with a mean
of 20.3 (±4.2). Also, their parity ranged from 0 to 12
with a mean of 4.9 (±2.6).
Abnormal vaginal bleeding was the most common
symptom reported by 143 (89.9 %) patients. Other symp-
toms were offensive vaginal discharge 91 (57.2) and pel-
vic pain 44 (27.7). The median duration of symptoms
before diagnosis was four months [3, 7]. Tumor size was
4.8 cm (±1.6) clinically and in 64 (57.7 %) patient’s upper
vaginal wall was invaded. Squamous cell carcinoma 137
(86.2 %) was the leading histological type, whereas
adenocarcinoma contributed 18 (11.3 %) and 4 (2.5 %)
were adenosquamous carcinoma.
An abdominal and pelvic CT was performed in 34.6 %
(n = 56) of cases, MRI in 62.9 % (n = 102). The pelvic
lymph nodes were achieved in 16.6 % of cases. In MRI
Tumor size was 41.6 (±16.8) mm and parametrial was
invaded in 57 (55.9 %) of cases.
Based on International Federation of Gynaecology and
Obstetrics classification for staging cervical cancer (ACS,
2008), 2 (1.4 %), 17 (12.3 %), 18 (13 %), 5 (3.6 %), 31
(22.5 %), 27 (19.6 %), 3 (2.2 %), 29 (21 %), 4 (2.9 %) and
2 (1.4 %) of cases, cancer stages were respectively IA,
IB1, IB2, IIA, IIB proximal, distal IIB, IIIA, IIIB, VIA and
VIB (Fig. 1).
One hundred fifty one (93.2 %) cases were treated in
our department. Table 2 shows their modalities. Over
half of patients 58.3 % (n = 88) were treated with a com-
bination of external beam radiation therapy (EBRT) and
Table 1 Clinical and para-clinical epidemiological
characteristics (n = 162)
Item Frequency (%) Range Mean (±standard
deviation)









Age of marriage (years) 12-30 17.9 (±3.6)
≤18 58 (63.7)
>18 33 (36.3)
Age of first pregnancy
(years)
14-36 20.3 (±4.2)














Pelvic pain 44 (27.7)
Haematuria 2 (1.3)




















Pelvic adenopathy 12 (21.4)
Table 1 Clinical and para-clinical epidemiological




Pelvic MRI 41.6 (±16.8)
Tumor size (mm) 102 (93)
Pelvic adenopathy 16 (15.7)
Parametrial invasion 57 (55.9)
Hemoglobin (g/dl) 11.8 (±1.8)
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weekly). Fifty (34 %) patients underwent surgery as their
initial treatment. Forty six (31.4 %) of these received post
operative radiotherapy or concomitant radio-chemotherapy
following surgery due to positive pelvic lymphnodes,
narrow or positive surgical margins or other poor risk
factors. The surgical procedure was Piver II; a modified
radical hysterectomy with annexectomy, which includes
removal of the uterus, cervix, upper one-fourth of the
vagina, and parametria. The surgeon also performs a bi-
lateral pelvic lymphadenectomy via laparotomy in 57
(85.1 %) cases, who brought 4.7 ± 3.9 nodes on the right
and 4.1 ± 3.7 nodes on the left, of which was only in-
vaded in 18/471 (3.82 %). Conventional laparoscopy or
robot-assisted laparoscopy was not available in our
hospital.
Table 3, summarizes the various therapeutic modalities
of different stages. Essentially our series contains 87
(63.1 %) patients with stage IIB and IIIB. These two
stages are essentially treated with concomitant radio-
chemotherapy.
With a mean follow-up of 51.6 months (2 to 109), we
recorded 19 (12.6 %) pelvic relapse and 15 (9.9 %) metas-
tases. The median time to onset was 19.4 months [2–33]
and [34-84]. The local control rate was 63.6 % (n = 96)
and 21 (13.9 %) patients were lost to follow-up. The over-
all survival (OS) at 3 years and 5 years was respectively
78.3 % and 73.6 % and the relapse-free survival (RFS) wasFig. 1 FIGO stage of disease
Table 2 Therapeutic modalities (n = 151)
Therapeutic modalities Frequency (%)
Concomitant radio-chemotherapy 66 (43.7)
Concomitant radio chemotherapy followed by surgery 22 (14.9)
Exclusive radiotherapy 12 (7.9)
Surgery followed by exclusive radiotherapy 25 (16.6)
Surgery followed by concomitant radio chemotherapy 21 (13.9)
Surgery alone 4 (2.6)
Palliative chemotherapy 1 (0.7)
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all patients who were lost to follow-up by phone and by
sending correspondence letter without resulting from
response.
As shown in Table 4, univariate analysis for clinical
parameters as risk factors for relapse, the only inde-
pendently significant variables were the Menopausal
status (p = 0.043) and parity (p = 0.010). Women with
advanced cervical cancer (distal IIB, III and IV) have a
higher rate of relapse 16 (25.8 %) than those with early
stage disease (I, IIA and proximal IIB) but there’s sta-
tistically no significant.
Multivariate analysis was not performed for our pa-
tient because of the small number of events.
Discussion
Cervical cancer has continued to have a devastating im-
pact on women’s health globally, and particularly in de-
veloping countries like Morocco where it has remained
the second most common cancer of women after breast
cancer [10].Table 3 Therapeutic modalities based on clinical stage
Modalities FIGO stage
IIIA IA IB1 IB2
Exclusive radiotherapy 0 0 2 0
0,0 % 0,0 % 16,7 % 0,0 %
Concomitant radio-chemotherapy 2 0 1 7
3,1 % 0,0 % 1,5 % 10,8
Surgery followed by exclusive
radiotherapy
0 1 10 3
0,0 % 5,9 % 58,8 % 17,6
Surgery followed by concomitant
radio chemotherapy
0 0 3 4
0,0 % 0,0 % 37,5 % 50,0
Concomitant radio chemotherapy
followed by surgery
1 0 0 2
4,5 % 0,0 % 0,0 % 9,1 %
Surgery alone 0 1 0 1
0,0 % 50,0 % 0,0 % 50,0
Palliative chemotherapy 0 0 0 0
0,0 % 0,0 % 0,0 % 0,0 %The demographic characteristics of the patients in this
study share similarities with results from several other
centers in Morocco and North Africa. For instance, the
mean age of patients in this study was 51.5 (±11.5) years
and the high mean parity 4.9 (±2.6) agrees with the re-
sults from other studies [14, 15]. Elsewhere in Africa,
the mean age was lower: 35 years in Dakar and 48 years
in Burkina Faso [16] and Madagascar [17]. The older
mean age in our study probably indicates a later expos-
ure to risk factors or reflects the belated consultation
and the lack of screening. These findings affirm that
menopausal status and grand multiparity were signifi-
cant causal risk factor for relapse.
The presenting complaints were essentially similar to
the reports in the literatures reviewed. The higher inci-
dence of abnormal vaginal bleeding reported in litera-
ture, affirm that is an important sign in cervical cancer.
Abnormal vaginal bleeding normally occurs as post-
coital, inter-menstrual, or postmenopausal bleeding.
Should every case of abnormal vaginal bleeding be
promptly investigated, cervical cancers would be diag-
nosed in early stages, at a time when there could be
hopes of cure. However, due to the illiteracy, poverty, ig-
norance, non-utilization of screening services, the major-
ity of the women present in late stage disease [13].
Initial evaluation of lymph nodes is commonly per-
formed with CT or RMI to minimize expense, biopsy of
suspected lymph nodes was not performed because it is
not a standard in cervical cancer but PET and PET/CT
are the imaging modalities used to provide information
for treatment decisions [18–21]. In our study, no pa-
tients have PET because we do not have a pet scan this
period. Actually, since 2012, we perform a PET/CT priorIIA IIB proximal IIB distal IIIB IVA IVB
0 0 3 5 2 0
0,0 % 0,0 % 25,0 % 41,7 % 16,7 % 0,0 %
1 18 18 16 1 1
% 1,5 % 27,7 % 27,7 % 24,6 % 1,5 % 1,5 %
0 3 0 0 0 0
% 0,0 % 17,6 % 0,0 % 0,0 % 0,0 % 0,0 %
1 0 0 0 0 0
% 12,5 % 0,0 % 0,0 % 0,0 % 0,0 % 0,0 %
2 9 5 3 0 0
9,1 % 40,9 % 22,7 % 13,6 % 0,0 % 0,0 %
0 0 0 0 0 0
% 0,0 % 0,0 % 0,0 % 0,0 % 0,0 % 0,0 %
0 0 0 0 0 1
0,0 % 0,0 % 0,0 % 0,0 % 0,0 % 100,0 %
Fig. 2 Global survival (GS) and relapse free survival (RFS)
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Table 4 Univariate analysis for clinical parameters associated
with the occurrence of relapse and/or metastasis
Characteristic Pelvic relapse and/or metastases P value
Yes (n = 31) No (n = 120)
Age 47.97 ± 10.317 52.11 ± 11.54 0.071
Menopausal status 0.043
Premenopausal 20 (27.4 %) 53 (72.6 %)
Postmenopausal 11 (14.1 %) 67 (85.9 %)
Age of marriage (years) 18.57 ± 2.84 17.79 ± 3.86 0.393
Age of first pregnancy (years) 21.86 ± 4.26 19.97 ± 4.97 0.124
Parity 3.79 ± 2.04 5.19 ± 2.65 0.010
Tumor size (cm) 5.19 ± 2.01 4.62 ± 1.50 0.168
Parametrial invasion 21 (22.1 %) 74 (77.9 %) 0.596
Histological type 0.281
Squamous cell carcinoma 24 (18.8 %) 104 (81.2 %)
Adenocarcinoma 6 (35.3 %) 11 (64.7 %)
Pelvic adenopathy 4 (23.5 %) 13 (76.5 %) 0.658
Hemoglobin (g/dl) 11.62 ± 1.61 11.97 ± 1.88 0.448
FIGO stage 0.052
I, IIA and proximal IIB 8 (12.3 %) 57 (87.7 %)




18 (27.3 %) 48 (72.7 %)
Radio-surgery 10 (14.7 %) 58 (85.3 %)
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ticular attention to lymph node metastases to provide
information to design radiation fields.
This study confirmed a delayed diagnosis of cervical
cancer in Morocco. In fact, the majority of patients were
presented in advanced stage (IB2-IVA) 117 (84.8 %). The
stage of diagnosis is the most important independent
prognostic factor [11, 12] and the survival rate at 5 years
decreases with stage of diagnosis: 85 % for stage IB to 0-
20 % for stage IV [22]. The mortality rate from cervical
cancer is greatly dependent on stage of diagnosis. In the
same way, the risk of pelvic recurrence increases with
the stage, 10 % for stage IB to more than 75 % for stage
IV [22, 23]. Finally, the risk of distant metastases also in-
creases with the stage, respectively 16 %, 26 %, 39 % and
75 % for stages I, II, III and IV [24]. Early Clinical diag-
nosis has been responsible for the reduction of cervical
cancer mortality achieved in developed countries before
cervical screening programs were adopted [25–27].
Our pathological data joined those already described
with the large predominance of squamous cell carcin-
oma [28, 29]; the most represented histological type in
our study was squamous cell carcinoma 137 (86.2 %);adenocarcinomas in 18 (11.3 %) and adenosquamous cell
carcinomas represented only 4 (2.5 %) of cervical cancer.
Over the past 40 years, multiple reports have docu-
mented the increase in relative distribution of adenocar-
cinoma compared to SCC in developed countries [30,
31]. In the USA, from 1973 to 1977, the proportions of
SCC and adenocarcinoma were 88 % and 12 %, respect-
ively; however, from 1993 to 1996, the proportions were
76 % and 24 % respectively [30].
In our study, treatment varied depending on the stage
of diagnosis. Radiotherapy was indicated for the different
stages. For advanced tumors (≥ stage II) concomitant
chemotherapy was associated with radiotherapy and /or
brachytherapy which join, in general, the recommenda-
tions for the management of invasive cervical cancer
[32]. Whereas surgery was a part of treatment modalities
in 71 (47.7 %) patients, which 50 (33.6 %) were operated
before admission to our department without multidiscip-
linary consultation meetings. The reasons of surgery
were intricate in our patients. It was indicated for very
early stages (IA and IB2) in 15 (21.1 %) cases and for pa-
tients with adenocarcinoma in 14 (19.7 %) cases. It was
also performed in 21 (29.5 %) case of poor response to
concomitant chemoradiotherapy. Some locally advanced
cervical cancer did not receive concomitant chemother-
apy because of 6 (25 %) kidney failure and 11 (45.8 %)
medical comorbidities or poor performance status
associated.
In our population, the rate of relapse increased with
the stage of diagnosis. This association shows the im-
portance of early diagnosis. Morocco is endowed, since
March 2010, of a National Plan for the Prevention and
Control of Cancer (PNPCC). Screening and treatment of
cervical cancer in Morocco represent the most crucial
priorities for PNPCC. A screening program for cervical
cancer is being introduced as well as other measures in
order to improve the opportunities of access to early
diagnosis by reducing geographical obstacles, multiply
the number of centers of diagnosis confirmation, reduce
economic barriers and provision facilities and resources.
The installation of a screening program for cervical can-
cer will be based on infrastructure and personnel, pri-
marily general practitioners, of primary level of health
care delivery. A pilot mass screening performed in Lyon
has clearly shown that intensive action, involving all
local stakeholders including general practitioners, could
reach a population of women who do not benefit from
an adequate gynecological following-up [33].
We conducted our study in radiotherapy department
of Military Hospital Mohamed V between January 2005
and February 2010. Despite recruits a small proportion
of cancer cases, our center is accounted the one of pub-
lic centers of cancer management in Morocco and we
believe that our population can be considered as a
Elmarjany et al. Gynecologic Oncology Research and Practice  (2015) 2:2 Page 7 of 8representative sample of cases of cervical cancer who ac-
cess to health system in Morocco.
Conclusion
Cervical cancer most often afflicts women in developing
countries. Our study confirmed a delayed diagnosis of
cervical cancer in Morocco and affirmed that menopausal
status and grand multiparity were significant causal risk
factor for relapse. As in the literature, advanced stages are
essentially treated with concomitant radio-chemotherapy.
Despite the limitation of our study, the results may rep-
resent an important tool in guiding the actions and mea-
sures of early diagnosis of cervical cancer in Morocco.
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